This morning, Peregrine Pharmaceuticals (NASDAQ: PPHM) released additional details regarding its revised analysis of bavituximab in non-small cell lung cancer. Today's release comes less than a week after investors totally misinterpreted clinical data on the drug used in pancreatic cancer, initially bidding up shares before a sharp sell-off later in the day. As Brenton Flynn outlines in the video below, this time around the investor reaction has been much more rational.
Peregrine Investors: Once Bitten, Twice Shy
By Brenton Flynn – Feb 19, 2013 at 11:40AM
Investors aren't too excited about this secondary data analysis